ArticleFrontiers in nuclear medicine2023
Quantitative imaging for
Article in Frontiers in nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- The predictive role of [European journal of nuclear medicine and molecular imaging · 2026Article
- Prospective head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Estimation and Correction of the Partial Volume Effect Using Personalized Phantoms of Lymph Node Metastases in Lutetium 177 SPECT/CT Dosimetry.Molecular imaging and biology · 2026Article
- Future of radiotheranostics.BMJ oncology · 2026Review
- Randomized Phase 2 Trial of an Extended and Flexible Dosing Schedule ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.